Key Takeaways
Extended Takeaways
- In the pooled 5-week EMERGENT 1–3 trials, XT separated from placebo on PANSS total and positive subscale scores at the first assessment, while PANSS negative symptom benefits did not reach statistical significance until week 3; this timing can help set expectations for early follow-up.
- Long-term extension data suggest durable benefit with XT: in EMERGENT-4, improvements were sustained through week 52, with 68.6% achieving ≥30% PANSS improvement, 37.1% achieving ≥50% improvement, and 82.9% showing at least a 1-point CGI-S improvement.
- Early gastrointestinal and anticholinergic effects appear front-loaded rather than cumulative; in EMERGENT-4, dry mouth (17.8%), constipation (9.9%), dyspepsia (8.6%), nausea (10.5%), vomiting (6.6%), and diarrhea (5.9%) typically arose within the first 2 weeks, were self-limited, and rarely led to discontinuation.
- Because trospium chloride absorption is reduced by food, XT should be taken without food; the report specifically notes that nausea and vomiting can be problematic if XT is administered after a patient has eaten.
- Medication reconciliation is especially important before starting XT because additive anticholinergic burden may worsen tolerability; the panel specifically advises trimming unnecessary agents such as diphenhydramine and reviewing bladder, COPD, Alzheimer’s disease, and Parkinson’s disease medications.
- The report identifies specific evidence gaps that should temper implementation decisions: recommendations reflect early experience in approximately 200 patients, and there are still no randomized head-to-head comparisons with standard antipsychotics or long-term functional outcome data.
